The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1467-1472.e1 , June 2008

Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa

Received 27 June 2007 ,Revised 10 March 2008 ,Accepted 18 March 2008.

References 

  1. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32
  2. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816–822
  3. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805
  4. Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant. 2007;39:1–9
  5. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10 secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004;172:5986–5993
  6. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor-β. J Exp Med. 2001;194:629–644
  7. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295–302
  8. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead box p3+ regulatory T cells. J Immunol. 2006;177:840–851
  9. Freitas A, Wildin RS. IPEX and FOXP3; clinical and research perspectives. J Autoimmun. 2005;25:56–62
  10. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterisation of Foxp3+CD4+CD25+ and IL-10- secreting CD4+CD25+ T cells during cure of colitis. J Immunol. 2006;177:5852–5860
  11. Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid- Grendelmeier P, Hijnen D, Knol EF, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol. 2006;117:176–183
  12. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Ruckert B, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425–1433
  13. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995–1004
  14. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo M-G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177:8338–8347
  15. Ruprecht C, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Co-expression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med. 2005;201:1793–1803
  16. Bochner BS, Schleimer RP. Mast cells, basophils and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev. 2001;179:5–15
  17. Hansen I, Klimek L, Mösges R, Hörmann K. Mediators of inflammation in the early and late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2004;4:159–163
  18. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004;363:608–615
  19. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199:1679–1688
  20. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–1034
  21. Aalberse R, van der Gaag CR, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130:722–727
  22. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy. 1999;29:497–506
  23. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252–3259
  24. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker M, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. J Immunol. 2007;178:4658–4666
  25. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107:87–93
  26. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol. 2005;116:73–79
  27. Wilson DR, Nouri-Aria KT, Walker SM, Pajno GB, O'Brien F, Jacobson MR, et al. Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 2001;107:971–976
  28. Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-β, and CTLA4. J Immunol. 2003;171:5012–5017
  29. Gerstmayr M, Ilk N, Schabussova I, Jahn-Schmid B, Egelseer EM, Sleytr UB, et al. A novel approach to specific allergy treatment: The recombinant allergen-S-Layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10 producing regulatory T cells. J Immunol. 2007;179:7270–7275
  30. Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, Cosmi L, et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol. 2007;120:429–436
  31. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-β to convert naïve CD25+CD4− cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178:2018–2027
  32. Mantel P-Y, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K, et al. Molecular mechanisms underlying Foxp3 induction in human T cells. J Immunol. 2006;176:3593–3602
  33. Morgan ME, van Bilsen JHM, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, et al. Expression of Foxp3 mRNA is not confined to CD4+CD25+ T regulatory cells in human. Hum Immunol. 2005;66:13–20

 Funding for this project was from the Medical Research Council UK. K.T.N.-A. was supported by the Advanced Drug Discovery Initiative, a collaborative project between Imperial College Trust and GlaxoSmithKline. ALK-Abelló, Hørsholm, Denmark, supported the clinical trial of grass pollen subcutaneous immunotherapy.

 Disclosure of potential conflict of interest: S. R. Durham has consulting arrangements with ALK-Abelló; has received research support from ALK-Abelló; is partially funded by the Immune Tolerance Network of the National Institutes of Health; and is on the speakers' bureau for ALK-Abelló, Allergy Therapeutics, and Stallergenes. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00597-6

doi: 10.1016/j.jaci.2008.03.013

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1467-1472.e1 , June 2008

Article Tools

* Image Usage & Resolution